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Aim Antipsychotics increase the risk of stroke. Their effect on myocardial infarction remains uncertain because people pre-
scribed and not prescribed antipsychotic drugs differ in their underlying vascular risk making between-person compar-
isons difficult to interpret. The aim of our study was to investigate this association using the self-controlled case series
design that eliminates between-person confounding effects.
Methods
and results
All the patients with a first recorded myocardial infarction and prescription for an antipsychotic identified in the Clinical
Practice Research Datalink linked to the Myocardial Ischaemia National Audit Project were selected for the self-
controlled case series. The incidence ratio of myocardial infarction during risk periods following the initiation of anti-
psychotic use relative to unexposed periods was estimated within individuals. A classical case–control study was under-
taken for comparative purposes comparing antipsychotic exposure among cases and matched controls. We identified
1546 exposed cases for the self-controlled case series and found evidence of an association during the first 30 days
after the first prescription of an antipsychotic, for first-generation agents [incidence rate ratio (IRR) 2.82, 95% confidence
interval (CI) 2.0–3.99] and second-generation agents (IRR: 2.5, 95% CI: 1.18–5.32). Similar results were found for the
case–control study for new users of first- (OR: 3.19, 95% CI: 1.9–5.37) and second-generation agents (OR: 2.55, 95%
CI: 0.93–7.01) within 30 days of their myocardial infarction.
Conclusion We found an increased risk of myocardial infarction in the period following the initiation of antipsychotics that was not
attributable to differences between people prescribed and not prescribed antipsychotics.
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Introduction
Antipsychotics are widely prescribed with a total of 9.3 million pre-
scriptions dispensed in England in 2011.1 Their cardiovascular risk
profile is of concern with users at an increased risk of death from
cardiac causes and stroke.2 –6 A recent study suggests that older
patients with dementia are at an increased risk of myocardial infarc-
tion (MI) shortly after antipsychotic initiation,7 but the question of
whether antipsychotics are associated with MI in the general
population is unanswered.8 As the underlying risk of MI in patients
with a major psychiatric illness is higher than in the general popula-
tion, there is a great scope for bias when estimating treatment
effects comparingpeopleprescribed andnotprescribedantipsychot-
ic drugs.9 –11 The aim of our study was to investigate this association
using the self-controlled case series (SCCS) design, where compari-
sons are made within individuals who have both the event of interest
and the exposure of interest, eliminating confounding due to
between-person differences.12
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Methods
Databases used
Data for this studywereprovided by theCArdiovasculardisease research
using Linked Bespoke studies and Electronic Records (CALIBER) pro-
gramme, established in 2011 to provide evidence across different
stages of research, in part by providing linkages of multiple electronic
heath records.13 This study was based on linking the national myocardial
infarction register [the Myocardial Ischaemia National Audit Project
(MINAP)] to primary care records collected and archivedby the UK Clin-
ical Practice Research Datalink (CPRD). Myocardial Ischaemia National
Audit Project facilitates comparisons of MI management between
hospitals in England and Wales in which patients with acute coronary
symptoms are admitted since 1999.13 Validated MINAP data provide in-
formation on key clinical indicators with regard to myocardial ischaemia.
Individual CPRD practices are linked with MINAP and all the patients
from these practices are linked if they have an event recorded in
MINAP. The CPRD contains the anonymized longitudinal electronic
medical records of 8% of all UK patients.14 Almost 50% of all patients
in the CPRD have at least 5 years of follow-up and data quality is high.
This study used the medical records of patients registered at one of
264 MINAP-linked UK general practices (GPs), comprising 2 625 818
active patients in November 2010.
Source population, outcome, and exposure
The source population was all the patients aged 18 years and older regis-
tered in the MINAP-linked CPRD. Patients had to have at least 1 year of
enrolment at their GP before entry into the study. Follow-up was cen-
sored at the earliest of the date the patient left the practice, death
date, switch of antipsychotic class, or the latest date of data collection.
Patients with an MI were identified in the CPRD if they had a code of
an incident MI in their medical file or if they were referred to the hospital
with a code of incident MI between 1987 and March 2010. Patients with
an MI were identified in MINAP, if they weredischarged from the hospital
with a diagnosis of an incident MI between January 2003 and August
2009. A validation study, using the same data sources, reported a high
validity of CPRD MI diagnoses: the positive predictive value of MI as
recorded in the CPRD database, using electrocardiographic and tropo-
nin recordings in MINAP as a gold standard, is 92%.15 Exposure was
defined as a recorded prescription for an antipsychotic. For the
purposes of this study, antipsychotics were classed as either first- or
second-generation antipsychotics. First-generation agents included
pimozide, butyrophenones, phenothiazines, and sulpiride. Second-
generation antipsychotics included amisulpride, clozapine, olanzapine,
quetiapine, and risperidone. Patients exposed to discontinued products
or prochlorperazine only were excluded as the indications for prochlor-
perazine, including severe nausea, vomiting and vertigo, were not
considered comparable with indications for other antipsychotics.
We searched for records suggesting (i) schizophrenia and psychosis,
(ii) mood disorders (including depression), (iii) dementia, and (iv)
other psychiatric indications at the time of MI. The duration of each
prescription was estimated by dividing the total quantity received by
the numeric daily dose prescribed. The median length of 28 days was
imputed if information on quantity or dose was missing. Where apparent
treatment breaks occurred, a period of up to 60 days was allowed during
which the patient was considered continuously exposed, allowing for
medication stockpiling and non-adherence.
The study complies with the Declaration of Helsinki and was approved
by the LSHTM Ethics committee (5743), CALIBER SOC and CPRD ISAC
(10_073) and is registered with ClinicalTrials.gov (NCT01236274).
Self-controlled case series study
The SCCS method is a type of a cohort study in which the relative risk is
based on within-person comparisons rather than between-person com-
parisons, with each person contributing to both the exposed and unex-
posed observation time.12 This means the confounding effects of
differences between patients are removed if these factors are fixed
over the observation period. Time-varying confounders, such as age,
can be controlled for. All the cases with a first recorded MI in CPRD or
MINAP and a first recorded antipsychotic prescription 12 months after
the start of the CPRD follow-up were selected as the study population.
The observation time was divided into risk windows: (i) 0–30 days
after starting treatment, (ii) 31–91 days after starting treatment, (iii)
the remaining exposed time, followed by (iv) a post-exposure 6-month
period divided into 60 day periods representing a gradual shift from full
exposure to an entirely unexposed state; the baseline period comprised
all remaining unexposed time (see Figure 1). Age was modelled explicitly
in 2-year age bands from 40 to 90 years with the youngest (18–40 years)
and oldest age group (.90 years) summarized. Subgroup analyses were
performed for users of first- and second-generation antipsychotics, for
Figure 1 Self-controlled case series design ‘myocardial infarction and antipsychotics’.
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patients with and without dementia and for patients with prior cardiovas-
cular disease (CVD).
An important assumption underpinning the SCCS is that observation
periods of individuals should end independently of the timing of the
outcome. When this assumption is violated (e.g. the outcome increases
the short-term risk of death), a recently developed extension of the
method should be used. Correcting for non-random censoring of follow-
up was necessary in this study as MI could lead to death and use of the
standard SCCS method may result in bias.16
Case–control study
Cases with a first recorded MI in the CPRD were randomly matched to up
to five controls with no prior MI and actively registered with CPRD on the
index date of the case by age, gender, and GP. Odds ratios (ORs) were cal-
culated, comparing antipsychotic exposure in cases with controls. Expos-
ure was defined as (i) any antipsychotic prescription within 90 days of the
index date or (ii) having received a prescription.90 days before the event
(former users) or (iii) first antipsychotic prescription within 30 days of the
index date (new users). Subgroup analyses were performed for users of
first-generation and second-generation antipsychotics. The risk estimates
of the new users were compared with the results of the SCCS study.
Odds ratios were calculated both crude and adjusted for diagnoses of
non-MI CVD, diabetes, hypertension, dyslipidaemia, CVD drugs use,
smoking, alcohol use, and body mass index (BMI) at the time of the
event. Clinical Practice Research Datalink medical records were used
to determine covariates using coding algorithms developed by the
CALIBER programme.
Secondary analyses
Several additional analyses were performed: (i) All SCCS analyses were
performed using both the standard and extended methods, to assess the
impact of follow-up time censoring. (ii) Since MINAP outcomes were
not included in the case–control study, the SCCS was repeated excluding
MINAP outcomes for comparability. (iii) The 60-day period bridging the
gap between prescriptions was shortened to 30 days or completely
omitted. (iv) A separate SCCS analysis was conducted to report on the as-
sociation between the use of prochloperazine and the risk of MI. (iv) The
effect of excluding patients with missing data was investigated.
Statistical methods
Incidence rate ratios for the SCCS study were calculated using conditional
Poisson regression. For the case–control study conditional logistic re-
gression was used to compute the crude and adjusted OR estimates.
Never use of antipsychotics was used as a baseline comparator. Analyses
were conducted using Stata, v11 (StataCorp, College Station, TX, USA).
The modified case series design included the same parameters as the
standard SCCS method: a parameter for the exposure of interest and a
parameter for age, with the age parameter containing a component de-
scribing the short-term impact of the event of interest on censoring. A
mixed exponential and Weibull model was used to model the density
of age at the end of observation, which depended on the age at the occur-
rence of the event and individual characteristics. All modified case series
analyses were performed in R, version 2.13.2.
Results
Identification of myocardial infarction
cases
In the MINAP-linked CPRD database, 39 345 patients had an incident
MI. Patients with ,12 months of follow-up and patients who could
not be matched to a suitable control were excluded (n ¼ 4147); 35
198 cases were successfully matched to 137 919 controls.
Within this primary study population, 31 746 patients were
exposed to prochlorperazine and/or discontinued products and
were excluded, as were 115 cases with an incident MI after their cen-
soring date (switch of antipsychotic drug). Lastly, 4687 patients (907
MI cases)wereexcludedas theywereprevalentusers.Aflowdiagram
showing how patients were selected is shown in Figure 2.
Results self-controlled case series
Ten thousand and five-hundred and seventy patients received an
antipsychotic and had an MI recorded in either CPRD or MINAP.
Twenty-four patients used first- and second-generationagents simul-
taneously and were excluded, leaving 1546 patients (Table 1). The
median observation period was 11 years with a single exposure
period lasting, on average, 3 months.
Using the extended SCCS design, there was evidence of an
increased risk of MI during the first 30 days after the first recorded
prescription of a first- generation antipsychotic [incidence rate
ratio (IRR) 2.82, 95% confidence interval (CI) 2.0–3.99] and during
the first 30 days following a repeat prescription (IRR: 1.95, 95% CI:
1.19–3.21) (Table 2). There was similar evidence of an association
between the prescription of second-generation agents and an in-
crease in the risk of MI during the first month of use (IRR: 2.5, 95%
CI: 1.18–5.32) but not thereafter (see Table 2). There was some evi-
dence of an increase in risk of an incident recorded MI during the
second and third month of exposure to first-generation antipsycho-
tics (IRR: 1.41, 95% CI: 1.04–1.9), and some evidence of an increase
in risk during any remaining exposed time thereafter for both first-
(IRR: 1.47, 95% CI: 1.12–1.93) and second-generation (IRR: 1.75,
95% CI 1.06–2.87) antipsychotics. The relative risk of MI decreased
during the 6-month post-exposure period after the use of second-
generation agents (Table 2).
There was no evidence that the risk differed between-patients
diagnosed with dementia and those without: The IRR was 3.1 (95%
CI: 1.0–9.6) during the first month of use of first-generation agents
for patients with dementia (n ¼ 83) and 2.73 (95% CI: 1.9–3.93)
for patients without dementia (n ¼ 1223). There were insufficient
data to estimate the risk of MI in users of second-generation agents
diagnosed with dementia (n ¼ 34).
For users of first-generation antipsychotics, there was no evidence
of any difference in risk between patients with recorded CVD prior
to their MI (IRR: 2.7, 95% CI: 1.69–4.31, n ¼ 681) and those without
(IRR: 2.72, 95% CI: 1.62–4.59, n ¼ 625). Some differences were
found between users of second-generation antipsychotic agents
with (IRR: 2.94, 95% CI: 1.13–7.64, n ¼ 124) and without prior
CVDs (IRR: 1.82, 95% CI: 0.52–6.29, n ¼ 116).
Comparison results self-controlled case
series and case–control study
About27 861caseswith an incidentMI in the CPRDwerematched to
108 234 controls (Table 3). Around 2% of patients were exposed to
antipsychotics during their follow-up period. Most (n ¼ 2521) were
exposed to first-generation antipsychotics and phenothiazines were
the most prescribed with 1552 exposed. Psychiatric morbidities,
such as schizophrenia and major depressive episodes, were more
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often recorded among cases than controls. Cases were more often
diagnosed with atherosclerotic disease, hypertension, diabetes, dys-
lipidaemia, and overweight at the time of their MI as well as more
likely to smoke than the control population.
The results of the case–control study are shown in Table 4. There
was evidence of an increased risk of MI up to 90 days after the receipt
of a prescription for a first-generation antipsychotic agent [OR: 1.38,
95% confidence interval (CI) 1.16–1.64]. There was no evidence of
an association between the current use of second-generation
agents and the recording of an MI (OR: 1.07, 95% CI: 0.73–1.57).
There was no evidence of an association between the former use
of any antipsychotic agent (use of antipsychotics up 90 days before
the event date) and the recording of an MI (OR: 0.91, 95% CI:
0.81–1.02 for first-generation agents and OR: 1.16, 95% CI: 0.71–
1.9 for second-generation agents).
The association between the riskof MI and antipsychotic exposure
during the first 30 days in the SCCS study was compared with the risk
of MI and exposure during a similar risk window of the case–control
study (first prescription received 1–30 days before a recorded MI).
For first-generation agents, the results of the case–control study
(OR: 3.19, 95% CI: 1.9–5.37) were very similar to the results of the
modified SCCS study (IRR: 2.82, 95% CI: 2.0–3.99). For second-
generation agents, the case–control study results (OR: 2.55, 95%
CI: 0.93–7.01) were also very similar to those of the SCCS
(IRR: 2.5, 95% CI: 1.18–5.32).
Results secondary analyses
Qualitatively, the secondary SCCS analyses gave similar results to
those obtained in the primary analysis (see Supplementary material
online). The results of the secondary case–control analysis, using
complete data only, showed strong evidence of an increased risk of
MI up to 90 days after the receipt of a prescription for a first-
generation antipsychotic agent (OR: 1.52, 95% CI: 1.21–1.92), but
no evidence of an increase after receipt of a second- generation
prescription (0.74, 95% CI: 0.46–1.21).
Discussion
We investigated the relationship between the use of antipsychotics
and the risk of an MI by performing a SCCS study and also a classical
case–control study for comparative purposes. Regardless of the
study design used, we found evidence that new users of antipsycho-
tics were at an increased risk of MI during the first month of drug use.
The increased risks were similar among those with and without diag-
nosed dementia or prior CVD.
Figure 2 Flow diagram showing patient population for the case–control study ‘myocardial infarction and antipsychotics’.
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Comparison with previous studies
The increased risk of cardiac arrhythmias caused by antipsychotic drug
usehasbeenshown inprevious studies.6,17,18While themechanismfor
the increase in risk of MI is not known, our results suggest that patients
with a susceptibility may experience an MI early on in the treatment,
independent of a history of cardiac disease, which could point to a trig-
gering effect caused by drug-induced changes in heart rate.
Few studies have looked at the association between antipsychotics
and MI. However, our results are similar to those of Pariente et al.7
who found that older patients using cholinesterase inhibitors were
at an increased risk of MI when concomitant treatment with antipsy-
chotics was initiated. They also found a strong increase in the risk of
MI during the first month of antipsychotic use [RR: 1.78 (1.26–2.52)]
after which the risk was similar to unexposed periods. Furthermore,
our results are in agreement with the results of a cohort study con-
ducted by Enger et al. who reported a five-fold higher risk of MI in
users of first-generation antipsychotic agents compared with non-
using control subjects.19 Differences in the strength of the effect
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Table 1 Demographic details and distribution of cardiovascular and behavioural risk factors of the self-controlled case
series study population at the time of the recording of an incident myocardial infarction
Cases with a first recorded MI and
antipsychotic prescription
Number 1546
Age (years) (SD) 70.24 (13.03)
Gender (%)
Males 56.02
Females 43.98
Cardiovascular comorbidities (%)
Atherosclerotic disease (including stroke, peripheral arterial disease) 805 (52.0)
The use of antiplatelets/anti-coagulants (excluding aspirin) 195 (12.6)
Aspirin 608 (39.2)
Hypertension (including the use of antihypertensive drugs) 1056 (68.3)
Diabetes mellitus (including the use of diabetic drugs) 231 (14.9)
Dyslipidaemia (including the use of lipid-lowering drugs) 376 (24.3)
Psychiatric co-morbidities (%)
Schizophrenia and psychotic episodes 89 (5.8)
Mood disorders (including depression) 557 (36)
Othera 79 (5.1)
Dementia 117 (7.6)
Behavioural risk (%)
Smoking (%)
Current 423 (27.4)
Ex 541 (35.0)
Non 526 (34.0)
Missing 56 (3.6)
Alcohol (%)
Excessive drinking 128 (8.3)
Current 913 (59.1)
Ex 66 (4.3)
Non 240 (15.5)
Missing 199 (12.9)
BMI (%)
BMI .25 762 (49.3)
BMI ,25 528 (34.2)
Missing 256 (16.6)
Antipsychotic prescription (%)
First generation 670 (43.3)
Second generation 86 (5.6)
Figures are numbers of patients and percentages.
aOther psychiatric co-morbidities include obsessive-compulsive disorder, phobias, and recorded visits to the psychiatrist without a recorded indication.
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may be explained by the inclusion of both prevalent and incident
cases of MI and users of antipsychotics diagnosed with schizophrenia
only by Enger et al.
In contrast, Nakagawa et al. reported no increase in risk in the first
time antipsychotic users up to 90 days before a first recorded hospi-
talization for MI [adjusted relative risk: 0.98 (0.88–1.09) for second-
generation agents and 0.99 (0.96–1.03) for first-generation
agents].20 We believe that these differences in results may partly
be explained by the exclusion of non-hospitalized MI cases by Naka-
gawa et al. A recent Canadian study showed that while patients with
schizophrenia visit their general practitioner more often than
patients without schizophrenia, they receive less specialized cardiac
care.21 By limiting the outcome to events recorded in the hospital,
we believe that some myocardial events may have been overlooked.
While we did not compare the increase in risk of MI between users
offirst- andsecond-generationantipsychoticagents, strongevidenceof
an increase in risk after receipt of a first-generation antipsychotic was
consistently found regardless of the study design used. The point esti-
mates for first-generation agents were higher than those reported for
second-generation agents. The point estimate reported in a study by
Huybrechts et al., in which antipsychotic-using US nursing home resi-
dentswere followed up for180days, suggests that the initiationof first-
generation antipsychotic use is associated with an increased risk of MI
compared with the use of second- generation agents (propensity
score-adjusted hazard ratio: 1.23, 95% CI: 0.82–1.82).22
Strengths and limitations
Our study population was relatively large, representative of the UK
population and included patients with and without dementia. We
included incident antipsychotic users only and censored follow-up
if patients switched between first- and second-generation antipsy-
chotics. We were therefore able to analyse the effects of both types
of antipsychotic separately. While we could not identify the precise in-
dication for antipsychotics, we found that 87% of patients had a
recorded psychiatric indication for antipsychotics with 75% of these
recorded within a year of the first prescription. We tried to avoid
extreme variability in underlying diagnoses by excluding patients
prescribed prochlorperazine only. Results of secondary analyses
showed a similar increase in risk of MI for users of prochlorperazine
only, which suggests that antipsychotic agents may be associated
with a temporary increase in risk of MI irrespective of the underlying
diagnosis.
We used a recently developed extended version of the SCCS
design as with the standard design bias may sometimes be introduced
when the outcome of interest increases the short-term risk of
death.23 Although MI clearly increases the risk of death, in this in-
stance our comparison of the standard and designs gave very
similar results, suggesting that such bias was avoided.
As with all studies using GP prescription data, we were not able to
confirm that medications wereobtained or used as directed and non-
adherence may particularly have affected the results of the SCCS as
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Table 2 Results self-controlled case series
Type of
anti-psychotic
Exposure Patient
years
n MIs Crude rate-ratio for MI [95%
confidence interval (CI)]
Age-adjusted rate ratio for MI
(95% CI) corrected for censoring
First generation Unexposed 11 748 1021 Baseline Baseline
Exposed periods first 1–30 days
of exposure
94 35 2.85 (2.02–4.02) 2.82 (2.0–3.99)
Exposed periods 1–30 days for
subsequent episodes of
exposurea
97 17 2.04 (1.25–3.34) 1.95 (1.19–3.21)
Exposed periods 31–90 days 330 49 1.44 (1.07–1.94) 1.41 (1.04–1.9)
Exposed periods .90 days 789 104 1.57 (1.21–2.06) 1.47 (1.12–1.93)
Post-exposure period 1–60 days 282 31 1.17 (0.81–1.68) 1.15 (0.8–1.66)
Post-exposure period 61–120
days
239 34 1.53 (1.08–2.17) 1.52 (1.07–2.16)
Post-exposure period 121–180
days
215 15 0.76 (0.46–1.28) 0.76 (0.45–1.27)
Second generation Unexposed 1927 175 Baseline Baseline
Exposed periods first 1–30 days
of exposure 19 8 2.75 (1.31–5.76) 2.5 (1.18–5.32)
Exposed periods 1–30 days for
subsequent episodes of
exposurea 5 0 na na
Exposed periods 31–90 days 42 7 1.22 (0.56–2.7) 1.1 (0.49–2.45)
Exposed periods .90 days 208 40 2.06 (1.32–3.21) 1.75 (1.06–2.87)
Post-exposure period 1–60 days 22 5 1.93 (0.77–4.85) 1.74 (0.67–4.46)
Post-exposure period 61–120
days 18 3 1.41 (0.44–4.55) 1.3 (0.4–4.25)
Post-exposure period 121–180
days 15 2 1.19 (0.29–4.88) 1.13 (0.27–4.7)
aExposure after treatment gaps.
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accurate recording of the timing of exposure and outcomes is an im-
portant underlying assumption of case-only designs. A surprising in-
crease in the risk of MI was found during the 60–120 days after the
end of the last recorded prescription of a first-generation anti-
psychotic agent. This may suggest that the date we assigned as the
end of a treatment course was underestimated due to medication
stockpiling and non-adherence in some instances. Alternatively, mul-
tiple testing may have led to chance findings.
Two study designs were used with different strengths and weak-
nesses. The main advantage of the SCCS over other observational
study designs is that patients act as their own control. As the
results of the case–control study were similar to the results of the
SCCS, confounding by known variables was unlikely to have had a
distinct effect on our study results. We looked for evidence that anti-
psychotic initiation may have coincided with other risk factors for MI
that change with time as an alternative explanation for our results: In
the week of the first antipsychotic prescription, we identified 11
patients also receiving a first ever prescription for another medica-
tion and four other patients were newly diagnosed with diseases
such as urinary infections. Excluding these 15 patients from the
main analyses had no material effect on the results. This suggests
other possible causes of MI did not tend to correlate with anti-
psychotic initiation. We acknowledge that protopathic bias cannot
be excluded, by which some patients may have received a prescrip-
tion for an antipsychotic due to prodromal symptoms of an MI
which was then diagnosed after antipsychotic treatment started.
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Table 3 Demographic details and distribution of cardiovascular and behavioural risk factors of study population at the
time of the recording of an incident myocardial infarction
Cases Controls P-value
Number 27 861 108 234
Age (years) (SD) 68.69 (13.1) 67.14 (13.0) ,0.001
Gender (%)
Males 65.97 68.8 ,0.001
Females 34.03 31.2
Cardiovascular comorbiditiesa (%)
Atherosclerotic disease (including stroke, peripheral arterial disease) 11 664 (41.9) 20 933 (19.3) ,0.001
The use of antiplatelets/anti-coagulants 2248 (8.1) 5158 (4.8) ,0.001
Hypertension (including the use of antihypertensive drugs) 16 475 (59.1) 43 341 (40.0) ,0.001
Diabetes mellitus (including the use of diabetic drugs) 3781 (13.6) 7628 (7.1) ,0.001
Dyslipidaemia (including the use of lipid-lowering drugs) 5925 (21.3) 14 546 (13.4) ,0.001
Psychiatric co-morbiditiesa (%)
Schizophrenia and psychotic episodes 259 (0.9) 747 (0.7) ,0.001
Mood disorders (including depression) 6708 (24.1) 21 288 (19.7) ,0.001
Otherb 748 (2.7) 2322 (2.1) ,0.001
Dementia 388 (1.4) 1445 (1.3) 0.028
Behavioural risk (%)
Smoking (%)
Current 7456 (26.8) 20 053 (18.5) ,0.001
Ex 9405 (33.8) 33 645 (31.1)
Missing 1970 (7.1) 9915 (9.2)
Alcohol—excessive drinking (%)
Current 2314 (8.3) 10 009 (9.2) ,0.001
Ex 897 (3.2) 2329 (2.2)
Missing 3954 (14.2) 19 393 (17.9)
BMI (%)
.25 14 992 (53.8) 52 083 (48.1) ,0.001
Missing 4529 (16.3) 21 834 (20.2)
Antipsychotic prescription (%)
First generation 660 (2.4) 1861 (1.7) ,0.001
Second generation 64(0.2) 200 (0.2)
Figures are numbers of patients and percentages.
aAll co-morbidities in the conditional logistic regression were considered as dichotomous.
bOther psychiatric co-morbidities include obsessive-compulsive disorder, phobias and recorded visits to the psychiatrist without a recorded indication.
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While the possibility of drug interactions or a temporal change in
underlying health state at the time of prescription cannot be ruled
out, the greatest association between antipsychotics and MI was
seen with the first ever exposure. Later exposures would also be
expected to occur during similar changes in underlying health or
with similar multiple prescriptions, suggesting a hypothesized drug
effect occurring early on during exposure.
Conclusions
TheriskofMI is around two- to three-foldhigher in themonth follow-
ing the initiation of antipsychotic treatment. The increased risk was
not attributable to differences between people prescribed and not
prescribed the drugs. Based on the results of the current study, the
size of the observed risk could be similar to that seen for COX2 inhi-
bitors.24 As antipsychotics are an effective intervention for some
major psychiatric conditions, the relatively small increased absolute
risk of MI is unlikely to alter their benefit–risk balance when used ap-
propriately.25 However, when used in unlicensed indications without
proven efficacy, such as dementia, the balance of risks and benefits is
likely to be less favourable.
Supplementary material
Supplementary material is available at European Heart Journal online.
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